secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001724521-25-000120
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus ends Phase 3 STAR-221 domvanalimab study on futility; no OS benefit
-------------------------------------------------------------------------

- Phase 3 STAR-221 of domvanalimab + zimberelimab + chemo vs nivolumab + chemo stopped for futility after IDMC review.
- Domvanalimab combo did not improve overall survival vs nivolumab + chemo; safety profile similar.
- Phase 2 EDGE-Gastric also discontinued; company and Gilead communicating with investigators.
- R&D focus shifts to HIF-2a inhibitor casdatifan and small molecule inflammation programs; MRGPRX2 inhibitor clinical entry expected 2026.
- Cash runway expected to fund operations until at least second half 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000120/0001724521-25-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000120/rcus-20251212.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer